<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Myeloid immune cells &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/myeloid-immune-cells/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 29 Sep 2025 16:41:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Myeloid immune cells &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Myeloid Immune Cells: A Promising New Target for Liver Cancer Immunotherapy</title>
		<link>https://bioengineer.org/myeloid-immune-cells-a-promising-new-target-for-liver-cancer-immunotherapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 29 Sep 2025 16:41:23 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Hepatoblastoma immunotherapy]]></category>
		<category><![CDATA[Myeloid immune cells]]></category>
		<category><![CDATA[Pediatric cancer research]]></category>
		<category><![CDATA[Spatial omics]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/myeloid-immune-cells-a-promising-new-target-for-liver-cancer-immunotherapy/</guid>

					<description><![CDATA[In a groundbreaking investigation into pediatric liver cancer, researchers from the Princess Máxima Center and UMC Utrecht have uncovered an unexpected abundance of myeloid immune cells within hepatoblastoma tumors. This revelation challenges previous assumptions about the immunological landscape of these tumors and opens novel pathways for therapeutic intervention, especially in the realm of immunotherapy for [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">273248</post-id>	</item>
	</channel>
</rss>
